Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- George A. Saviolakis, M.D.
DynPort Vaccine Company LLC
Study Director - William Swiderski
DynPort Vaccine Company LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Miami Research Associates
Miami, Florida, United States
- University Clinical Research, Inc
Pembroke Pines, Florida, United States
- Johnson County Clin-Trials
Lenexa, Kansas, United States
- Center for Pharmaceutical Research
Kansas City, Missouri, United States
- Wake Research Associates
Raleigh, North Carolina, United States
- Clinical Research Associates of Tidewater
Norfolk, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2008
- Primary completion
- 31 Mar 2010
- Completion
- 31 Dec 2010
- Last update posted
- 2 Dec 2011
- Registered enrollment
- 440
- Registry id
- NCT00764634
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.